



Original Article

The Impact of Idiopathic Intracranial Hypertension on Cardiovascular Disease Risk Among UK Women: An Obesity-Adjusted Analysis

Ahmed Y. Azzam^{1,2,3,*}, Mahmoud M. Morsy^{1,4}, Mohamed Hatem Ellabban⁵, Ahmed M. Morsy⁶, Adham Adel Zahran⁶, Mahmoud Nassar^{7,8}, Omar S. Elsayed¹, Adam Elswedy¹, Osman Elamin⁹, Ahmed Saad Al Zomia¹⁰, Hana J. Abukhadajah¹¹, Hammam A. Alotaibi¹², Oday Atallah¹³, Mohammed A. Azab¹⁴, Muhammed Amir Essibayi^{2,15}, Adam A. Dmytriw^{16,17}, Mohamed D. Morsy¹⁸, David J. Altschul^{2,15}

1-Faculty of Medicine, October 6 University 6th of October City, Giza, Egypt

2-Montefiore-Einstein Cerebrovascular Research Lab, Albert Einstein College of Medicine Bronx, NY, USA

3-Director of Clinical Research and Clinical Artificial Intelligence, American Society for Inclusion, Diversity, and Health Equity (ASIDE) Delaware, USA

4-Clinical Research Fellow, American Society for Inclusion, Diversity, and Health Equity (ASIDE) Delaware, USA

5-Faculty of Medicine, Al-Azhar University Cairo, Egypt

6-Kasr Alainy Faculty of Medicine, Cairo University Hospitals, Cairo University Cairo, Egypt

7-Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo New York, NY, USA

8-Founder, American Society for Inclusion, Diversity, and Health Equity (ASIDE) Delaware, USA

9-Department of Neurosurgery, Jordan Hospital Amman, Jordan

10-College of Medicine, King Khalid University Abha, Saudi Arabia

11-Medical Research Center, Hamad Medical Corporation Doha, Qatar

12-Ophthalmology Department, Prince Sultan Military Medical City Riyadh, Saudi Arabia

13-Department of Neurosurgery, Hannover Medical School Hannover, Germany

14-Department of Neurosurgery, Cleveland Clinic Foundation Cleveland, OH, USA

15-Department of Neurological Surgery, Montefiore Medical Center, Albert Einstein College of Medicine Bronx, NY, USA

16-Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard University Boston, MA, USA

17-Neurovascular Centre, Divisions of Therapeutic Neuroradiology & Neurosurgery, St. Michael's Hospital, University of Toronto Toronto, ON, Canada

18-College of Medicine, King Khalid University Abha, Saudi Arabia

ARTICLE INFO

Article history:

Received 28 Oct. 2024

Received in revised form 15 Nov. 2024

Accepted 17 Nov. 2024

Published 27 Nov. 2024

Keywords:

Idiopathic Intracranial Hypertension

Pseudotumor Cerebri

Stroke

Ischemic Stroke

Cardiovascular Disease

ABSTRACT

Introduction: Idiopathic intracranial hypertension (IIH) is associated with increased cardiovascular disease (CVD) risk, but the relative contributions of obesity versus IIH-specific factors remain unclear. This study aims to disentangle the effects of obesity and IIH on stroke and CVD risk, building upon previous research suggesting a two-fold increased risk of cardiovascular events in women with IIH compared to BMI-matched controls.

Methods: We conducted an obesity-adjusted risk analysis using Indirect Standardization analysis based on the Adderley et al. study, which utilized data from a cohort of 2,760 women with IIH and 27,125 matched healthy controls from The Health Improvement Network (THIN) database. We employed innovative statistical models to adjust for the confounding effects of obesity, estimating the risk of ischemic stroke and cardiovascular disease attributable to IIH independent of obesity. Four distinct models were used to elucidate the complex interrelationships between IIH, obesity, and CVD risk.

Results: Our analysis revealed that IIH confers additional cardiovascular risk beyond that attributed to obesity alone. Risk ratios for various cardiovascular outcomes were consistently elevated across models comparing IIH patients to controls within the same obesity strata. A striking synergistic effect between IIH and obesity was observed, with the composite CVD risk reaching a risk ratio of 6.19 (95% CI: 4.58-8.36, $p < 0.001$) in obese IIH patients compared to non-obese controls.

Conclusions: This study provides compelling evidence for a nuanced relationship between IIH, obesity, and cardiovascular risk. IIH appears to confer substantial cardiovascular risk independent of obesity, necessitating a paradigm shift in IIH management to encompass comprehensive cardiovascular risk mitigation. Further research is needed to elucidate the underlying mechanisms and develop targeted interventions for this unique patient population.

*Corresponding author: Ahmed Y. Azzam, MD, MEng, Montefiore-Einstein Cerebrovascular Research Lab, Albert Einstein College of Medicine, Bronx, NY, USA. Email: ahmedyazzam@gmail.com

Published by the American Society for Inclusion, Diversity, and Equity in Healthcare (ASIDE). ISSN (Print) 3065-9671, ISSN (Online) 3065-968X. © 2024 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). Hosting by ASIDE Journals.

Citation: Azzam AY, Morsy MM, Ellabban MH, et al. The Impact of Idiopathic Intracranial Hypertension on Cardiovascular Disease Risk Among UK Women: An Obesity-Adjusted Analysis. ASIDE Int Med. 2024;1(1):1-10 doi:10.71079/h1fr8h68

1. Introduction

Idiopathic intracranial hypertension (IIH) is a condition characterized by elevated intracranial pressure of unknown etiology, typically manifesting as papilledema with associated risks of visual loss and chronic disabling headache [1]. The incidence and economic burden of IIH are rising in parallel with global obesity trends [2]. While obesity is a well-established risk factor for IIH, with over

90% of patients being obese [3], the relationship between IIH and cardiovascular disease (CVD) risk remains poorly understood.

In the United States, studies indicate an incidence increase from 1.6 to 2.4 per 100,000 person-years in the general population, rising dramatically to 15-19 per 100,000 in women of childbearing age [4]. This rising disease burden encompasses both economic impacts, with annual costs exceeding millions of dollars in the US, and significant quality of life deterioration, including chronic pain, vision problems, and psychological distress [5, 6].

Adderley et al. conducted a retrospective case-control population-based matched controlled cohort study using 28 years of data from The Health Improvement Network (THIN) database in the United Kingdom. THIN database is a longitudinal primary care database containing anonymized electronic health records from over 17 million patients in the United Kingdom, provides researchers with comprehensive clinical data for epidemiological studies and healthcare research. [7]. Their study suggested that women with IIH have a two-fold increased risk of cardiovascular events compared to BMI-matched controls. However, the mechanisms underlying this elevated risk and the relative contributions of obesity versus IIH-specific factors remained unclear.

The relationship between IIH and CVD risk involves multiple pathophysiological mechanisms beyond adiposity alone. Neuroendocrine dysfunction in IIH is characterized by elevated endogenous testosterone and androstenedione levels, distinct from exogenous supplementation or polycystic ovary syndrome (PCOS) [8]. This hormonal dysregulation may affect both cerebrospinal fluid (CSF) dynamics and cardiovascular function [9]. Additionally, the current literature studies demonstrate elevated levels of pro-inflammatory cytokines in IIH patients, potentially contributing to both intracranial pressure elevation and vascular dysfunction [9]. IIH patients exhibit distinct metabolic profiles, including altered glucose homeostasis and lipid metabolism, which may independently contribute to cardiovascular risk [9, 10]. Several additional risk factors may contribute to both IIH and CVD, including hormonal contraceptive use, vitamin A metabolism, sleep apnea, and chronic kidney disease [11, 12, 10].

Building upon Adderley et al.'s [7] findings, our study aims to disentangle the effects of obesity and IIH on stroke risk specifically. Obesity is a known independent risk factor for stroke, with an average hazard ratio (HR) of 2.29 reported in large-scale evidence [13]. By adjusting for this obesity-related risk, we seek to isolate the potential contribution of IIH itself to stroke incidence. Our study employs an established methodological approach adapted from epidemiological research on obesity [14, 15] to simulate predicted ischemic stroke and CVD events in both IIH and control groups under normative weight conditions. This approach has been previously used in obesity literature [16, 17].

Understanding the relationship between IIH and their associated risks, independent of obesity, has important clinical implications. If IIH itself confers additional cardiovascular risk, it may warrant more aggressive management of modifiable risk factors and earlier implementation of preventive strategies in this patient population. Furthermore, elucidating this potential association's mechanisms could reveal new therapeutic targets for reducing cardiovascular morbidity in IIH. Our study aims to build upon the foundational work of Adderley et al. [7] to further investigate the complex interplay between IIH, obesity, and the associated risks. By employing innovative statistical methods to adjust for the confounding effects

of obesity, we aim to provide crucial insights into the cardiovascular implications of IIH and inform evidence-based management strategies for this increasingly prevalent condition.

2. Methods

Building upon the foundational work of Adderley et al. [7], we conducted a retrospective analysis using data from their paper, which was originally obtained through THIN, a large UK primary care database. Our study focused on women with IIH and matched controls, aiming to elucidate the independent effect of IIH on stroke and cardiovascular risks, distinct from the influence of obesity. Patients were excluded from the Adderley et al. [7], study whether they had different diagnostic or clinical codes for conditions that could mimic IIH, specifically hydrocephalus, cerebral venous thrombosis, or any other cause of elevated intracranial pressure (ICP).

Additionally, female patients were excluded from the baseline cohort selection if they did not have at least one year of registration with an eligible general practice before cohort entry to ensure adequate documentation of baseline covariates. For the analysis of individual CVD outcomes, patients with a record of the specific outcome of interest at baseline were excluded from the corresponding analysis; for composite CVD analysis, patients with any CVD at baseline were excluded; for type 2 diabetes analysis, patients with either type 1 diabetes or type 2 diabetes at baseline were excluded. For sensitivity analyses, additional exclusions were applied, including excluding women diagnosed with IIH after age 60 since IIH is rare among older adults, and there may be potential misclassification errors in this age group.

2.1. Study Population and Data Source:

We utilized the cohort established by Adderley et al. [7], comprising 2,760 women with IIH and 27,125 matched controls. Participants were identified from THIN database records spanning January 1, 1990, to January 17, 2018. Controls were matched to IIH patients based on age, body mass index (BMI), and sex, with up to 10 controls per IIH case.

2.2. Outcome Measures:

Our primary outcome of interest was the incidence of composite CVD, heart failure, ischemic heart disease (IHD), ischemic stroke, transient ischemic attack (TIA), hypertension, and type 2 diabetes mellitus. We extracted the relevant data from the corresponding paper, following the coding and identification methods described by Adderley et al. [7].

2.3. Statistical Analysis:

We extended the original analysis to estimate the independent effect of IIH on stroke and cardiovascular risks, accounting for the confounding effect of obesity. Our approach involved indirect standardization and adjustment with the application of a standardized morbidity ratio (SMR) approach [18, 19, 20, 21, 22], adapted to account for obesity as a confounding variable in relationship with IIH in women around the UK. To estimate the incidence of events in both the IIH and control cohorts under a hypothetical scenario of normal weight, we employed an adjustment method based on the average HR for obesity contributing to the event risk in women compared to healthy weight women in 13-year intervals from the literature. This approach operates under the assumption that the HR remains constant throughout the 13-year study period and that the impact of obesity on the estimated events is independent of IIH status. We utilized Python 3.12 and its associated statistical

libraries to perform our statistical analysis. Initially, we calculated the observed HR for each event in the IIH group compared to the control group. Subsequently, we adjusted this observed HR by obesity HR to estimate the HR for IIH independent of obesity. Based on the current evidence, the average estimated HR of obesity contributing to composite CVD is 2.89 [23, 24, 25, 26, 27, 28, 29]. For obesity, ischemic stroke, and TIA risk, it is estimated around HR = 1.72 [23, 26, 30, 31, 32, 33, 34, 35, 36]. For obesity and heart failure risk, it is estimated around HR = 2.61 [37, 38, 39, 40, 41, 42, 43]. For obesity and hypertension risk, it is estimated around HR = 2.09 [44, 45, 46, 47, 48, 49, 50]. For obesity and IHD risk, it is estimated around HR = 1.8 [23, 24, 26, 28, 30, 51, 52]. For obesity and type 2 diabetes mellitus risk, it is estimated to be around HR = 4.0 [53, 54, 55, 56, 57, 58, 59, 60].

We calculated the HR for each event in the IIH group compared to the control group through the following equation:

$$HR = \frac{IIH \text{ events}}{IIH \text{ total}} \bigg/ \frac{Control \text{ events}}{Control \text{ total}}$$

We then adjusted this observed HR by the established HR for obesity in association with the potential risk to estimate the HR for IIH independent of obesity:

$$Adjusted \text{ HR} = \frac{Observed \text{ HR}}{Obesity \text{ HR}}$$

Using this adjusted HR, we predicted the number of events in both groups under normative weight conditions: For the IIH group:

$$\text{Predicted IIH events} = \frac{Adjusted \text{ HR} \times Control \text{ events} \times IIH \text{ total}}{Control \text{ total}}$$

For the control group:

$$\text{Predicted Control events} = \frac{Control \text{ events}}{Obesity \text{ HR}}$$

Using this adjusted HR, we calculated the predicted number of events in the IIH and control groups under the assumption of normal weight. This was accomplished by applying the adjusted HR to the control group event rate and scaling for the respective group sizes. For the control group, we divided the observed events by obesity HR to estimate events under normal weight conditions.

This method allows for a comparative analysis of event risk between IIH and control populations while attempting to control the confounding effect of obesity. It provides insight into the potential independent risk associated with IIH and allows for estimating event rates under hypothetical normal weight conditions.

2.4. Ethical Considerations:

This study adhered to the ethical approval obtained by Adderley et al. [7] from the NHS South-East Multicenter Research Ethics Committee. We did not involve direct analysis of the dataset, but rather built customized statistical modeling based on the provided data and metrics from the Adderley et al. research paper [7].

3. Results

3.1. Baseline Characteristics:

The original retrospective cohort study by Adderley et al. [7] encompassed 29,885 participants, stratified into 2,760 (9.2%) women with IIH and 27,125 (90.8%) controls. The incident cohort comprised 48.2% and 46.7% of the IIH and control groups, respectively.

Both cohorts were predominantly under 60 (98.1% IIH, 95.2% control), with identical median ages of 32.1 years (IQR: 25.62-42.00 IIH, 25.71-42.06 control). Socioeconomic status, assessed via Townsend Deprivation Quintiles, showed a comparable distribution between groups, with a slight overrepresentation of controls in the least deprived quintiles. Smoking habits differed significantly: the IIH cohort exhibited higher rates of current smoking (30.8% vs 22.6%) and lower rates of non-smoking (46.5% vs 55.5%).




Figure 1: Model 1 – Obese IIH vs Obese Control Forest Plot.

Anthropometric data revealed a marginally higher median BMI in the IIH group (34.80, IQR: 29.30-40.30) compared to controls (34.30, IQR: 29.00-39.70). Notably, both groups demonstrated a high prevalence of obesity (BMI >30), affecting 62.6% and 60.9% of the IIH and control cohorts, respectively. Comorbidity profiles and pharmacological interventions showed distinct patterns. The IIH cohort demonstrated a higher prevalence of migraine (21.0% vs. 11.9%), hypertension (13.8% vs. 9.2%), and marginally increased rates of lipid-lowering medication use (6.5% vs. 5.8%). Furthermore, baseline cardiovascular morbidity was more pronounced in the IIH group, with elevated rates of ischemic heart disease (1.3% vs. 0.9%) and ischemic stroke/TIA (1.7% vs 0.7%). Interestingly, type 2 diabetes mellitus prevalence was slightly lower in the IIH cohort (4.7% vs. 5.2%) (Table 1).

3.2. Statistical Analysis:

This analysis employed four distinct statistical models to elucidate the complex interrelationships between IIH, obesity, and CVD risk. These models were strategically designed to disentangle the individual and combined effects of IIH and obesity on CVD outcomes.

Model 1 (Obese IIH vs. Obese Control) was constructed to isolate the effect of IIH within an obese population, effectively controlling for the confounding factor of adiposity. Model 2 (Obese IIH vs. Non-obese Control) provided a comprehensive view of the combined impact of IIH and obesity compared to individuals without either condition. Model 3 (Non-obese IIH vs. Obese Control) offered a unique perspective, juxtaposing the cardiovascular risks associated with IIH in non-obese individuals against those attributed to obesity alone. Model 4 (Non-obese IIH vs. Non-obese Control) isolated the impact of IIH in a non-obese population, providing critical insights into the condition's effects independent of obesity, (Table 2).


Our findings revealed a nuanced and clinically significant relationship between IIH, obesity, and cardiovascular risk. In Model 1 (Figure 1), IIH was consistently associated with elevated risks across all measured outcomes. The risk ratios (RR) ranged from 1.54 (95%

Table 1: Baseline Characteristics of the Included Individuals in the Original Study


Variable	Women With IIH (Exposed Group)	Women Without IIH (Control Group)
Population (n, %)	2760 (9.2%)	27,125 (90.8%)
Incident cohort	1331 (48.2%)	12,679 (46.7%)
Population aged <60 years	2709 (98.1%)	25,811 (95.2%)
Age, median (IQR), years	32.1 (25.62–42.00)	32.1 (25.71–42.06)
Townsend Deprivation Quintile		
1 (Least deprived)	361 (13.1%)	4268 (15.7%)
2	381 (13.8%)	4397 (16.2%)
3	532 (19.3%)	5174 (19.1%)
4	538 (19.5%)	5122 (18.9%)
5 (Most deprived)	454 (16.5%)	4134 (15.2%)
Missing data	494 (17.9%)	4030 (14.9%)
Smoking Status		
Nonsmoker	1284 (46.5%)	15,058 (55.5%)
Ex-smoker	502 (18.2%)	4573 (16.9%)
Smoker	849 (30.8%)	6134 (22.6%)
Missing data	125 (4.5%)	1360 (5.0%)
BMI, median (IQR)	34.80 (29.30–40.30)	34.30 (29.00–39.70)
Body Mass Index (BMI) Category		
<25	246 (8.9%)	2561 (9.4%)
25–30	416 (15.1%)	4203 (15.5%)
>30	1728 (62.6%)	16,514 (60.9%)
Missing data	370 (13.4%)	3847 (14.2%)
Current lipid prescription	180 (6.5%)	1572 (5.8%)
Migraine	580 (21.0%)	3247 (11.9%)
Outcomes at Baseline		
Heart failure	8 (0.3%)	58 (0.2%)
Ischemic heart disease (IHD)	35 (1.3%)	245 (0.9%)
Ischemic stroke / TIA	46 (1.7%)	189 (0.7%)
Hypertension	380 (13.8%)	2500 (9.2%)
Type 2 Diabetes Mellitus	130 (4.7%)	1425 (5.2%)

IIH, Idiopathic Intracranial Hypertension; IQR, Interquartile Range; BMI, Body Mass Index; IHD, ischemic heart disease; TIA, Transient Ischemic Attack

CI: 1.27-1.86, $p<0.001$) for type 2 diabetes mellitus to 2.28 (95% CI: 1.62-3.21, $p<0.001$) for stroke/TIA. This uniform pattern of risk elevation suggests that IIH confers additional cardiovascular risk beyond that attributed to obesity alone, a finding of relevance in clinical risk stratification.

**Figure 2:** Model 2 – Obese IIH vs Non-Obese Control Forest Plot.

Model 2, (Figure 2) demonstrated even more pronounced risk elevations, with the composite CVD risk reaching a striking RR of 6.19 (95% CI: 4.58-8.36, $p<0.001$). This marked increase suggests a potential synergistic effect between IIH and obesity on cardiovascular health, which may have significant implications for patient management and therapeutic interventions. Notably, the risk for heart failure in this model was particularly elevated (RR 5.75, 95% CI: 3.17-10.42, $p<0.001$), highlighting the need for vigilant cardiac monitoring in obese IIH patients. Interestingly, Model 3, (Figure 3), presented a more complex picture. The non-significant risk ratios for most outcomes in this model suggest that non-obese individuals with IIH may not have significantly different CVD risks compared to obese individuals without IIH. This finding underscores the profound impact of obesity on cardiovascular health, potentially rivaling or even overshadowing the effects of IIH in certain contexts. Of note in this model was the significantly reduced risk of type 2 diabetes mellitus in non-obese IIH patients compared to obese controls (RR 0.40, 95% CI: 0.28-0.57, $p<0.001$). This intriguing paradox may offer valuable insights into the underlying pathophysiology of both conditions and warrants further mechanistic investigation.

**Figure 3:** Model 3 – Non-Obese IIH vs Obese Control Forest Plot.

Model 4, (Figure 4) provided robust corroboration of IIH as an independent risk factor, with significant risk elevations observed across all outcomes in non-obese IIH patients compared to non-obese controls. The composite CVD risk in this model (RR 2.18, 95% CI: 1.41-3.39, $p<0.001$) closely mirrored that observed in Model 1, further supporting the notion that IIH confers cardiovascular risk independent of obesity status. This finding has important

implications for the management of non-obese IIH patients, who may be at underappreciated cardiovascular risk.

Ranking the CVD risks for IIH patients based on our data reveals the highest risk ratios in Model 2, with the following hierarchy: composite CVD (RR 6.19) > heart failure (RR 5.75) > stroke/TIA (RR 3.93) > ischemic heart disease (RR 3.76). This stratification underscores the critical importance of addressing both IIH and obesity in our highest-risk patients and may inform the development of targeted screening and intervention protocols. The data on type 2 diabetes mellitus warrant special consideration. The 6.14-fold increased risk (95% CI: 4.90-7.70, $p < 0.001$) observed in obese IIH patients compared to non-obese controls (Model 2) is particularly striking. This marked elevation, coupled with the paradoxical risk reduction in non-obese IIH patients (Model 3), suggests a complex interplay between IIH, obesity, and metabolic dysfunction. These findings raise intriguing questions about potential shared pathophysiological mechanisms and may open new avenues for research into the neuroendocrine aspects of IIH. Hypertension, a known risk factor for both CVD and IIH progression, showed a consistent pattern of elevated risk across Models 1, 2, and 4. However, the reduced risk observed in Model 3 (RR 0.77, 95% CI: 0.61-0.97, $p = 0.03$) adds another layer of complexity to our understanding of the relationship between IIH, obesity, and blood pressure regulation.




Figure 4: Model 4 – Non-Obese IIH vs Non-Obese Control Forest Plot.

4. Discussion

Our obesity-adjusted analysis uncovered several significant findings that advance our understanding of how IIH influences CVD outcomes. Our primary analysis demonstrated that IIH independently raises CVD risk, as we observed consistent risk elevations (RR= 1.54 to 2.28) across CVD outcomes in our obesity-matched cohorts. Perhaps our most striking finding was the synergistic interaction between IIH and obesity; we found a 6.19-fold increased risk of composite CVD events (95% CI: 4.58-8.36, $p < 0.001$) in obese IIH patients compared to non-obese controls. Through our modeling, we also discovered a metabolic relationship: non-obese IIH patients showed CVD risks comparable to obese controls, which are significantly higher than non-obese controls (RR 2.18, 95% CI: 1.41-3.39, $p < 0.001$). We were particularly intrigued by the paradoxical relationship we observed with type 2 diabetes risk, which was elevated in obese IIH patients but reduced in non-obese IIH patients compared to obese controls, suggesting more complex metabolic mechanisms than previously recognized (**Figure 5**).

IIH → Cardiovascular Risk Pathway



Bidirectional relationship through shared pathophysiological pathways

Figure 5: IIH and CVD Risk Pathway.

The consistent elevation of risk ratios across Models 1 and 4, which compare IIH patients to controls within the same obesity strata, strongly suggests a distinct pathophysiological process intrinsic to IIH that exacerbates cardiovascular vulnerability. This finding aligns with emerging research on the neuroendocrine and metabolic perturbations in IIH, including recent metabolomic profiling by O'Reilly MW et al. [21] revealed a unique signature of altered androgen metabolism in CSF of IIH patients, characterized by elevated levels of testosterone and androstenedione. This androgen excess may represent a crucial link between IIH and cardiovascular risk through multiple mechanisms, including vascular dysfunction, inflammatory modulation, and metabolic dysregulation. Duckles and Miller [61] demonstrated that testosterone could induce vasoconstriction through both genomic and non-genomic pathways, potentially contributing to hypertension and altered cerebrovascular autoregulation in IIH.

The chronic elevation of ICP, a characteristic of IIH, may have direct and indirect effects on cardiovascular functions. Recent work by Wardlaw et al. [62] on the glymphatic system and intracranial fluid dynamics suggests that altered CSF flow and clearance in IIH may impair the removal of metabolic waste products from the brain. This accumulation of potentially toxic metabolites could exacerbate oxidative stress and vascular inflammation, contributing to the observed CVD risk.

The striking risk elevations observed in Model 2 (Obese IIH vs. Non-obese Control) reveal a synergistic interaction between IIH and obesity that amplifies CVD risk beyond the sum of their individual effects. This synergy likely arises from the convergence of multiple pathophysiological processes, including adipokine dysregulation, neuroendocrine activation, and hemodynamic alterations. Recent work by Hornby et al. [63] demonstrates that IIH patients exhibit a distinct adipokine signature, with particularly elevated CSF leptin levels. The combination of systemic and central adipokine dysregulation may create a uniquely pro-inflammatory and pro-thrombotic state. Moreover, the evidence by Markey K et al. [64] suggests that IIH patients may have altered cortisol metabolism, potentially exacerbating the metabolic and CVD consequences of obesity-related hypothalamic-pituitary-adrenal axis dysfunction.

The paradoxical findings regarding type 2 diabetes risk in our study—elevated in obese IIH patients but reduced in non-obese IIH patients compared to obese controls—challenge our current understanding of metabolic risk in IIH. This observation may be explained by the concept of "metabolic flexibility" proposed by Goodpaster and Sparks [65]. In non-obese IIH patients, the altered androgen metabolism and potential changes in adipose tissue function may confer a degree of metabolic protection. The

Table 2: Risk Contribution Calculations According to Different Hazard Regression Models.

Outcome / Characteristic	Women With IHH (Exposed Group)	Women Without IHH (Control Group)	P-value
Composite CVD			
Population, No.	2613	26,356	NA
Outcome events, No. (%)	68 (2.5)	328 (1.2)	NA
Person-years	12,809	132,930	NA
Crude incidence rate per 1000 person-years	5.31	2.47	NA
Follow-up, median (IQR), years	3.50 (1.34–7.11)	3.72 (1.51–7.39)	NA
Adjusted HR (95% CI)			
Model 1	2.15 [1.66–2.79]	NA	<.001**
Model 2	6.19 [4.58–8.36]	NA	<.001**
Model 3	0.76 [0.50–1.15]	NA	0.2
Model 4	2.18 [1.41–3.39]	NA	<.001**
Heart Failure			
Population, No.	2735	26,989	NA
Outcome events, No. (%)	17 (0.6)	78 (0.3)	NA
Person-years	13,445	136,357	NA
Crude incidence rate per 1000 person-years	1.26	0.57	NA
Follow-up, median (IQR), years	3.58 (1.38–7.26)	3.77 (1.52–7.50)	NA
Adjusted HR (95% CI)			
Model 1	2.21 [1.31–3.74]	NA	<.001**
Model 2	5.75 [3.17–10.42]	NA	<.001**
Model 3	0.91 [0.42–1.97]	NA	0.81
Model 4	2.37 [1.04–5.39]	NA	0.04*
Ischemic Heart Disease (IHD)			
Population, No.	2698	26,749	NA
Outcome events, No. (%)	27 (0.9)	131 (0.5)	NA
Person-years	13,216	134,521	NA
Crude incidence rate per 1000 person-years	2.04	0.97	NA
Follow-up, median (IQR), years	3.56 (1.37–7.20)	3.73 (1.51–7.42)	NA
Adjusted HR (95% CI)			
Model 1	2.10 [1.39–3.17]	NA	<.001**
Model 2	3.76 [2.42–5.85]	NA	<.001**
Model 3	1.17 [0.68–1.99]	NA	0.57
Model 4	2.09 [1.20–3.65]	NA	<.01*
Stroke / Transient Ischemic Attack (TIA)			
Population, No.	2674	26,755	NA
Outcome events, No. (%)	40 (1.5)	181 (0.7)	NA
Person-years	13,115	135,271	NA
Crude incidence rate per 1000 person-years	3.05	1.34	NA
Follow-up, median (IQR), years	3.51 (1.34–7.17)	3.76 (1.52–7.47)	NA
Adjusted HR (95% CI)			
Model 1	2.28 [1.62–3.21]	NA	<.001**
Model 2	3.93 [2.73–5.66]	NA	<.001**
Model 3	1.37 [0.89–2.09]	NA	0.15
Model 4	2.36 [1.51–3.67]	NA	<.001**
Hypertension			
Population, No.	2232	23,566	NA
Outcome events, No. (%)	148 (6.2)	1059 (4.3)	NA
Person-years	10,505	115,800	NA
Crude incidence rate per 1000 person-years	14.09	9.15	NA
Follow-up, median (IQR), years	3.20 (1.26–6.40)	3.48 (1.43–6.94)	NA
Adjusted HR (95% CI)			
Model 1	1.54 [1.30–1.83]	NA	<.001**
Model 2	3.22 [2.68–3.86]	NA	<.001**
Model 3	0.77 [0.61–0.97]	NA	0.03*
Model 4	1.61 [1.26–2.05]	NA	<.001**
Type 2 Diabetes Mellitus			
Population, No.	2510	24,901	NA
Outcome events, No. (%)	120 (4.6)	799 (3.1)	NA
Person-years	12,300	125,947	NA
Crude incidence rate per 1000 person-years	9.76	6.34	NA
Follow-up, median (IQR), years	3.49 (1.34–6.94)	3.62 (1.47–7.27)	NA
Adjusted HR (95% CI)			
Model 1	1.54 [1.27–1.86]	NA	<.001**
Model 2	6.14 [4.90–7.70]	NA	<.001**
Model 3	0.40 [0.28–0.57]	NA	<.001**
Model 4	1.59 [1.09–2.32]	NA	0.02*

* Denotes statistical significance, ** Denotes high statistical significance

IHH, Idiopathic Intracranial Hypertension; CVD, Cardiovascular Disease; IQR, Interquartile Range; IHD, ischemic heart disease; CI, Confidence Interval.

evidence by Mariniello et al. [66] on androgen effects on adipose tissue suggests that certain androgen profiles can enhance insulin sensitivity and improve glucose uptake in adipocytes. The specific androgen milieu in IIH may thus have differential effects depending on the overall metabolic context. Conversely, in obese IIH patients, this potential metabolic benefit may be overwhelmed by the profound insulin resistance and chronic inflammation associated with obesity. The interaction between obesity-related metabolic dysfunction and IIH-specific neuroendocrine perturbations may create a "perfect storm" for accelerated progression to type 2 diabetes [66].

Our findings necessitate a paradigm shift in the approach to cardiovascular risk management in IIH patients. We propose a multi-tiered strategy that includes enhanced risk stratification, targeted interventions, personalized metabolic management, and neuroendocrine modulation. The development of IIH-specific CVD risk calculators that incorporate novel biomarkers such as CSF androgen levels, adipokine profiles, and measures of intracranial pressure dynamics could significantly improve risk assessment in this population. Exploration of IIH-specific pharmacological interventions that address the unique pathophysiology of CVD risk in this population is warranted. For example, the potential use of selective androgen receptor modulators (SARMs) to mitigate the adverse cardiovascular effects of androgen excess while preserving potential metabolic benefits merits investigation.

Future research directions should include longitudinal studies employing advanced imaging techniques to elucidate the temporal relationship between IIH onset, progression, and cardiovascular remodeling. Multi-omics approaches integrating genomics, transcriptomics, and metabolomics could unravel the molecular mechanisms underlying the observed synergy between IIH and obesity in cardiovascular risk. Interventional trials exploring the potential cardioprotective effects of CSF diversion procedures or novel pharmacological agents targeting ICP regulation, are crucial. Additionally, investigation of sex-specific aspects of cardiovascular risk in IIH is essential, given the strong female predominance of the condition and the potential interaction with sex hormones.

The findings from our study reveal a complex, multifaceted relationship between IIH, obesity, and CVD risk that challenges existing paradigms and opens new frontiers in personalized medicine. The independent risk conferred by IIH, the synergistic effects of obesity, and the paradoxical metabolic findings underscore the need for a nuanced, mechanism-based approach to cardiovascular risk management in this unique patient population. As we continue to unravel the intricate pathophysiology of IIH, we move closer to developing targeted interventions that may not only alleviate the neurological symptoms of the condition but also mitigate its long-term cardiovascular consequences. The implications of our findings extend beyond IIH, offering potential insights into the broader interplay between neuroendocrine function, metabolic regulation, and cardiovascular health. The methodology of our paper has several limitations; at first, the approach assumes that the HR and the values provided from the original data and HR for obesity remain constant over the 13-year period and is applicable to both the IIH group and control group.

Secondly, it assumes that the effect of obesity on the events is independent of IIH status in each patient. Thirdly, the predicted events are based on the average HR for obesity from the current literature, which may not be fully representative of the study population in larger populations or another cohort. Also, the adjusted for IIH independent from obesity should be interpreted with caution, as

it is an estimation based on the available data and assumptions. To further validate the findings, it would be better to perform tailored individual-level data analysis based on BMI subgroup analysis and sensitivity tests for IIH patients and counting for other potential confounding variables in the cohort. Additionally, conducting a prospective study that directly compares IIH patients with normal weight controls would provide more comprehensive evidence for the independent effect of IIH on the proposed events.

5. Conclusions

Through our findings, we have established compelling evidence that IIH independently contributes to CVD risk beyond obesity alone. Our statistical modeling has revealed that IIH operates through both independent and obesity-synergistic pathways to elevate CVD risk. We consistently observed elevated risks across our obesity-stratified models, leading us to believe that IIH involves an intrinsic pathophysiological process that worsens CVD outcomes vulnerability. These findings align with emerging research on neuroendocrine dysregulation in IIH. Based on our results, we strongly advocate for a fundamental shift in IIH management to include comprehensive CVD risk assessment and mitigation. We believe developing IIH-specific CVD risk assessment tools and targeted interventions should be a priority. While we acknowledge the limitations of our study, including our assumptions about hazard ratio consistency and obesity effects, we have established a crucial foundation for future studies. We recommend prospective studies comparing IIH patients with normal-weight controls and deeper investigation of underlying mechanisms through multi-omics approaches. Our findings have significant implications for both clinical practice and future research in IIH management.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding Source

The project described was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through CTSA award number: UM1TR004400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Acknowledgments

None

Institutional Review Board (IRB)

Additional Institutional Review Board approval was not required for this study. This work is a secondary analysis that used only aggregate, previously published summary data reported by Adderley et al. [7], whose original study was approved by the NHS South-East Multicentre Research Ethics Committee. No individual patient-level or identifiable data were accessed at any stage; the results presented here are customized statistical models built on the published metrics of that study, consistent with the ethical considerations described in Section 2.4.

Informed Consent

Informed consent was not required for this study. No individual patient-level or identifiable data were accessed. All analyses were

derived from aggregate results already published by Adderley et al. [7], for which participant consent requirements were addressed in the original study.

Large Language Model

No generative artificial intelligence or large language model tools were used in the preparation of this manuscript.

Authors Contribution

AYA and MMM contributed equally to this work and were responsible for study conceptualization, data collection, analysis, and manuscript writing. MHE, AMM, AAZ, OSE, and AE assisted with data collection and analysis. OE, ASA, HJA, HAA, OA, and MAA provided methodological and technical support. MAE, AAD, and MDM contributed clinical expertise and critical review. MN assisted with project administration. DJA and AAD supervised the project. All authors reviewed and approved the final version of the manuscript. AYA serves as the corresponding author and is responsible for all communication regarding this work.

Data Availability

All data supporting the findings of this study are included in the article. Additional information is available from the corresponding author upon reasonable request.

References

- Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, et al. Idiopathic intracranial hypertension: consensus guidelines on management. *J Neurol Neurosurg Psychiatry*. 2018;89(10):1088-100. [PMID: 29903905, PMCID: PMC6166610, <https://doi.org/10.1136/jnnp-2017-317440>].
- Mollan SP, Aguiar M, Evison F, Frew E, Sinclair AJ. The expanding burden of idiopathic intracranial hypertension. *Eye (Lond)*. 2019;33(3):478-85. [PMID: 30356129, PMCID: PMC6460708, <https://doi.org/10.1038/s41433-018-0238-5>].
- Daniels AB, Liu GT, Volpe NJ, Galetta SL, Moster ML, Newman NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). *Am J Ophthalmol*. 2007;143(4):635-41. [PMID: 17386271, <https://doi.org/10.1016/j.ajo.2006.12.040>].
- Kilgore KP, Lee MS, Leavitt JA, Mokri B, Hodge DO, Frank RD, et al. Re-evaluating the Incidence of Idiopathic Intracranial Hypertension in an Era of Increasing Obesity. *Ophthalmology*. 2017;124(5):697-700. [PMID: 28187976, PMCID: PMC5637544, <https://doi.org/10.1016/j.ophtha.2017.01.006>].
- Committee NIIHSGW, Wall M, McDermott MP, Kiebertz KD, Corbett JJ, Feldon SE, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. *JAMA*. 2014;311(16):1641-51. [PMID: 24756514, PMCID: PMC4362615, <https://doi.org/10.1001/jama.2014.3312>].
- Kalyvas AV, Hughes M, Koutsarnakis C, Moris D, Liakos F, Sakas DE, et al. Efficacy, complications and cost of surgical interventions for idiopathic intracranial hypertension: a systematic review of the literature. *Acta Neurochir (Wien)*. 2017;159(1):33-49. [PMID: 27830325, <https://doi.org/10.1007/s00701-016-3010-2>].
- Adderley NJ, Subramanian A, Nirantharakumar K, Yiangou A, Gokhale KM, Mollan SP, et al. Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom. *JAMA Neurol*. 2019;76(9):1088-98. [PMID: 31282950, PMCID: PMC6618853, <https://doi.org/10.1001/jamaneurol.2019.1812>].
- O'Reilly MW, Westgate CS, Hornby C, Botfield H, Taylor AE, Markey K, et al. A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. *JCI Insight*. 2019;4(6). [PMID: 30753168, PMCID: PMC6483000, <https://doi.org/10.1172/jci.insight.125348>].
- Colman BD, Boonstra F, Nguyen MN, Raviskanthan S, Sumithran P, White O, et al. Understanding the pathophysiology of idiopathic intracranial hypertension (IIH): a review of recent developments. *J Neurol Neurosurg Psychiatry*. 2024;95(4):375-83. [PMID: 37798095, <https://doi.org/10.1136/jnnp-2023-332222>].
- Yiangou A, Mollan SP, Sinclair AJ. Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms. *Nat Rev Neurol*. 2023;19(12):769-85. [PMID: 37957260, <https://doi.org/10.1038/s41582-023-00893-0>].
- Alimajstorovic Z, Mollan SP, Grech O, Mitchell JL, Yiangou A, Thaller M, et al. Dysregulation of Amino Acid, Lipid, and Acylpyruvate Metabolism in Idiopathic Intracranial Hypertension: A Non-targeted Case Control and Longitudinal Metabolomic Study. *J Proteome Res*. 2023;22(4):1127-37. [PMID: 36534069, PMCID: PMC10088035, <https://doi.org/10.1021/acs.jproteome.2c00449>].
- Libien J, Kupersmith MJ, Blamer W, McDermott MP, Gao S, Liu Y, et al. Role of vitamin A metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial. *J Neurol Sci*. 2017;372:78-84. [PMID: 28017254, PMCID: PMC5290478, <https://doi.org/10.1016/j.jns.2016.11.014>].
- Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. *Stroke*. 2010;41(5):e418-26. [PMID: 20299666, <https://doi.org/10.1161/STROKEAHA.109.576967>].
- Greenland S, Morgenstern H. Confounding in health research. *Annu Rev Public Health*. 2001;22(1):189-212. [PMID: 11274518, <https://doi.org/10.1146/annurev.publhealth.22.1.189>].
- Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *Am J Epidemiol*. 2016;183(8):758-64. [PMID: 26994063, PMCID: PMC4832051, <https://doi.org/10.1093/aje/kwv254>].
- Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. 2014.
- Preston SH, Mehta NK, Stokes A. Modeling obesity histories in cohort analyses of health and mortality. *Epidemiology*. 2013;24(1):158-66. [PMID: 23211348, PMCID: PMC3870658, <https://doi.org/10.1097/EDE.0b013e3182770217>].
- Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. John Wiley sons; 2013.
- Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. *Epidemiology*. 2003;14(3):300-6. [PMID: 12859030].
- Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. *Pharmacoepidemiol Drug Saf*. 2006;15(5):291-303. [PMID: 16447304, <https://doi.org/10.1002/pds.1200>].
- Hernan M, Robins J. Causal inference: What if. Boca Raton: Chapman hill/crc. 2020.
- Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. *Biometrics*. 1998;54(3):948-63. [PMID: 9750244].
- Schmiegelow MD, Andersson C, Kober L, Andersen SS, Olesen JB, Jensen TB, et al. Prepregnancy obesity and associations with stroke and myocardial infarction in women in the years after childbirth: a nationwide cohort study. *Circulation*. 2014;129(3):330-7. [PMID: 24146252, <https://doi.org/10.1161/CIRCULATIONAHA.113.003142>].
- Li TY, Rana JS, Manson JE, Willett WC, Stampfer MJ, Colditz GA, et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. *Circulation*. 2006;113(4):499-506. [PMID: 16449729, PMCID: PMC3210835, <https://doi.org/10.1161/CIRCULATIONAHA.105.574087>].

25. Song X, Tabak AG, Zethelius B, Yudkin JS, Soderberg S, Laatikainen T, et al. Obesity attenuates gender differences in cardiovascular mortality. *Cardiovasc Diabetol*. 2014;13:144. [PMID: 25928355, PMCID: PMC4212094, <https://doi.org/10.1186/s12933-014-0144-5>].
26. Dikaoui P, Bjorck L, Adiels M, Lundberg CE, Mandalenakis Z, Manhem K, et al. Obesity, overweight and risk for cardiovascular disease and mortality in young women. *Eur J Prev Cardiol*. 2021;28(12):1351-9. [PMID: 34647583, <https://doi.org/10.1177/2047487320908983>].
27. Medina-Inojosa JR, Batsis JA, Supervia M, Somers VK, Thomas RJ, Jenkins S, et al. Relation of Waist-Hip Ratio to Long-Term Cardiovascular Events in Patients With Coronary Artery Disease. *Am J Cardiol*. 2018;121(8):903-9. [PMID: 29482851, PMCID: PMC6053270, <https://doi.org/10.1016/j.amjcard.2017.12.038>].
28. Kip KE, Marroquin OC, Kelley DE, Johnson BD, Kelsey SF, Shaw LJ, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. *Circulation*. 2004;109(6):706-13. [PMID: 14970104, <https://doi.org/10.1161/01.CIR.0000115514.44135.A8>].
29. Czernichow S, Kengne AP, Stamatakis E, Hamer M, Batty GD. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies. *Obes Rev*. 2011;12(9):680-7. [PMID: 21521449, PMCID: PMC4170776, <https://doi.org/10.1111/j.1467-789X.2011.00879.x>].
30. Kurth T, Gaziano JM, Rexrode KM, Kase CS, Cook NR, Manson JE, et al. Prospective study of body mass index and risk of stroke in apparently healthy women. *Circulation*. 2005;111(15):1992-8. [PMID: 15837954, <https://doi.org/10.1161/01.CIR.0000161822.83163.B6>].
31. Sanchez-Inigo L, Navarro-Gonzalez D, Fernandez-Montero A, Pastrana-Delgado J, Martinez JA. Risk of incident ischemic stroke according to the metabolic health and obesity states in the Vascular-Metabolic CUN cohort. *Int J Stroke*. 2017;12(2):187-91. [PMID: 28134052, <https://doi.org/10.1177/1747493016672083>].
32. Zahn K, Linseisen J, Heier M, Peters A, Thorand B, Nairz F, et al. Body fat distribution and risk of incident ischemic stroke in men and women aged 50 to 74 years from the general population. The KORA Augsburg cohort study. *PLoS One*. 2018;13(2):e0191630. [PMID: 29401461, PMCID: PMC5798769, <https://doi.org/10.1371/journal.pone.0191630>].
33. Chen MQ, Shi WR, Wang HY, Sun YX. Sex Differences of Combined Effects Between Hypertension and General or Central Obesity on Ischemic Stroke in a Middle-Aged and Elderly Population. *Clin Epidemiol*. 2021;13:197-206. [PMID: 33732027, PMCID: PMC7956891, <https://doi.org/10.2147/CLEP.S295989>].
34. Chaudhary D, Khan A, Gupta M, Hu Y, Li J, Abedi V, et al. Obesity and mortality after the first ischemic stroke: Is obesity paradox real? *PLoS One*. 2021;16(2):e0246877. [PMID: 33566870, PMCID: PMC7875337, <https://doi.org/10.1371/journal.pone.0246877>].
35. Horn JW, Feng T, Morkedal B, Strand LB, Horn J, Mukamal K, et al. Obesity and Risk for First Ischemic Stroke Depends on Metabolic Syndrome: The HUNT Study. *Stroke*. 2021;52(11):3555-61. [PMID: 34281375, <https://doi.org/10.1161/STROKEAHA.120.033016>].
36. Yatsuya H, Toyoshima H, Yamagishi K, Tamakoshi K, Taguri M, Harada A, et al. Body mass index and risk of stroke and myocardial infarction in a relatively lean population: meta-analysis of 16 Japanese cohorts using individual data. *Circ Cardiovasc Qual Outcomes*. 2010;3(5):498-505. [PMID: 20699444, <https://doi.org/10.1161/CIRCOUTCOMES.109.908517>].
37. Cordola Hsu AR, Xie B, Peterson DV, LaMonte MJ, Garcia L, Eaton CB, et al. Metabolically Healthy/Unhealthy Overweight/Obesity Associations With Incident Heart Failure in Postmenopausal Women: The Women's Health Initiative. *Circ Heart Fail*. 2021;14(4):e007297. [PMID: 33775111, PMCID: PMC11978397, <https://doi.org/10.1161/CIRCHEARTFAILURE.120.007297>].
38. Padwal R, McAlister FA, McMurray JJ, Cowie MR, Rich M, Pocock S, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. *Int J Obes (Lond)*. 2014;38(8):1110-4. [PMID: 24173404, <https://doi.org/10.1038/ijo.2013.203>].
39. Halldin AK, Schaufelberger M, Lernfelt B, Bjorck L, Rosengren A, Lissner L, et al. Obesity in Middle Age Increases Risk of Later Heart Failure in Women-Results From the Prospective Population Study of Women and H70 Studies in Gothenburg, Sweden. *J Card Fail*. 2017;23(5):363-9. [PMID: 27940334, <https://doi.org/10.1016/j.cardfail.2016.12.003>].
40. Morkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway. *J Am Coll Cardiol*. 2014;63(11):1071-8. [PMID: 24345592, <https://doi.org/10.1016/j.jacc.2013.11.035>].
41. Kawada T. Metabolically healthy obesity and cardiovascular events: A risk of obesity. *Diabetes Obes Metab*. 2022;24(4):763. [PMID: 34927325, <https://doi.org/10.1111/dom.14628>].
42. Chandramouli C, Tay WT, Bamadhaj NS, Tromp J, Teng TK, Yap JLL, et al. Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. *PLoS Med*. 2019;16(9):e1002916. [PMID: 31550265, PMCID: PMC6759142, <https://doi.org/10.1371/journal.pmed.1002916>].
43. Kenchaiah S, Ding J, Carr JJ, Allison MA, Budoff MJ, Tracy RP, et al. Pericardial Fat and the Risk of Heart Failure. *J Am Coll Cardiol*. 2021;77(21):2638-52. [PMID: 34045020, PMCID: PMC8218602, <https://doi.org/10.1016/j.jacc.2021.04.003>].
44. Lee SK, Kim SH, Cho GY, Baik I, Lim HE, Park CG, et al. Obesity phenotype and incident hypertension: a prospective community-based cohort study. *J Hypertens*. 2013;31(1):145-51. [PMID: 23079679, <https://doi.org/10.1097/HJH.0b013e32835a3637>].
45. Kabootari M, Akbarpour S, Azizi F, Hadaegh F. Sex specific impact of different obesity phenotypes on the risk of incident hypertension: Tehran lipid and glucose study. *Nutr Metab (Lond)*. 2019;16:16. [PMID: 30858870, PMCID: PMC6391753, <https://doi.org/10.1186/s12986-019-0340-0>].
46. Lewandowska M, Wieckowska B, Sajdak S. Pre-Pregnancy Obesity, Excessive Gestational Weight Gain, and the Risk of Pregnancy-Induced Hypertension and Gestational Diabetes Mellitus. *J Clin Med*. 2020;9(6). [PMID: 32599847, PMCID: PMC7355601, <https://doi.org/10.3390/jcm9061980>].
47. Nurdiantami Y, Watanabe K, Tanaka E, Pradono J, Anme T. Association of general and central obesity with hypertension. *Clin Nutr*. 2018;37(4):1259-63. [PMID: 28583324, <https://doi.org/10.1016/j.clnu.2017.05.012>].
48. Curhan GC, Chertow GM, Willett WC, Spiegelman D, Colditz GA, Manson JE, et al. Birth weight and adult hypertension and obesity in women. *Circulation*. 1996;94(6):1310-5. [PMID: 8822985, <https://doi.org/10.1161/01.cir.94.6.1310>].
49. Gus M, Fuchs SC, Moreira LB, Moraes RS, Wiehe M, Silva AF, et al. Association between different measurements of obesity and the incidence of hypertension. *Am J Hypertens*. 2004;17(1):50-3. [PMID: 14700512, <https://doi.org/10.1016/j.amjhyper.2003.08.010>].
50. Behboudi-Gandevani S, Ramezani Tehrani F, Hosseinpahan F, Khalili D, Cheraghi L, Kazemijalilseh H, et al. Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study. *Fertil Steril*. 2018;110(7):1377-86. [PMID: 30503137, <https://doi.org/10.1016/j.fertnstert.2018.08.046>].
51. Freedman DS, Williamson DF, Croft JB, Balles C, Byers T. Relation of body fat distribution to ischemic heart disease. The National Health and Nutrition Examination Survey I (NHANES I) Epidemiologic Follow-up Study. *Am J Epidemiol*. 1995;142(1):53-63. [PMID: 7785674, <https://doi.org/10.1093/oxfordjournals.aje.a117545>].
52. Quesada O, Lauzon M, Buttle R, Wei J, Suppogu N, Kelsey SF, et al. Body weight and physical fitness in women with ischaemic heart disease: does physical fitness contribute to our understanding of the obesity paradox in women? *Eur J Prev Cardiol*. 2022;29(12):1608-14. [PMID: 35244151, PMCID: PMC9440958, <https://doi.org/10.1093/eurjpc/zwac046>].
53. Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. Ectopic fat obesity presents the greatest risk for incident type 2 diabetes: a population-based longitudinal study. *Int J Obes (Lond)*. 2019;43(1):139-48. [PMID: 29717276,

- <https://doi.org/10.1038/s41366-018-0076-3>].
54. Lee DH, Keum N, Hu FB, Orav EJ, Rimm EB, Willett WC, et al. Comparison of the association of predicted fat mass, body mass index, and other obesity indicators with type 2 diabetes risk: two large prospective studies in US men and women. *Eur J Epidemiol*. 2018;33(11):1113-23. [PMID: 30117031, <https://doi.org/10.1007/s10654-018-0433-5>].
 55. Park SK, Ryoo JH, Oh CM, Choi JM, Jung JY. Longitudinally evaluated the relationship between body fat percentage and the risk for type 2 diabetes mellitus: Korean Genome and Epidemiology Study (KoGES). *Eur J Endocrinol*. 2018;178(5):513-21. [PMID: 29523634, <https://doi.org/10.1530/EJE-17-0868>].
 56. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. *Am J Epidemiol*. 1997;145(7):614-9. [PMID: 9098178, <https://doi.org/10.1093/oxfordjournals.aje.a009158>].
 57. Anagnostis P, Paparodis RD, Bosdou JK, Bothou C, Macut D, Goulis DG, et al. Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies. *Endocrine*. 2021;74(2):245-53. [PMID: 34176074, <https://doi.org/10.1007/s12020-021-02801-2>].
 58. Sluik D, Boeing H, Montonen J, Pischon T, Kaaks R, Teucher B, et al. Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. *Am J Epidemiol*. 2011;174(1):22-34. [PMID: 21616928, <https://doi.org/10.1093/aje/kwr048>].
 59. Yang J, Qian F, Chavarro JE, Ley SH, Tobias DK, Yeung E, et al. Modifiable risk factors and long term risk of type 2 diabetes among individuals with a history of gestational diabetes mellitus: prospective cohort study. *BMJ*. 2022;378:e070312. [PMID: 36130782, PMCID: PMC9490550, <https://doi.org/10.1136/bmj-2022-070312>].
 60. Hong S, Park JH, Han K, Lee CB, Kim DS, Yu SH. Association Between Obesity and Cardiovascular Disease in Elderly Patients With Diabetes: A Retrospective Cohort Study. *J Clin Endocrinol Metab*. 2022;107(2):e515-27. [PMID: 34597374, <https://doi.org/10.1210/clinem/dgab714>].
 61. Duckles SP, Miller VM. Hormonal modulation of endothelial NO production. *Pflugers Arch*. 2010;459(6):841-51. [PMID: 20213497, PMCID: PMC2865573, <https://doi.org/10.1007/s00424-010-0797-1>].
 62. Wardlaw JM, Benveniste H, Nedergaard M, Zlokovic BV, Mestre H, Lee H, et al. Perivascular spaces in the brain: anatomy, physiology and pathology. *Nat Rev Neurol*. 2020;16(3):137-53. [PMID: 32094487, <https://doi.org/10.1038/s41582-020-0312-z>].
 63. Hornby C, Mollan SP, Botfield H, O'Reilly MW, Sinclair AJ. Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention. *J Neuroophthalmol*. 2018;38(4):522-30. [PMID: 29985799, PMCID: PMC6215484, <https://doi.org/10.1097/WNO.0000000000000684>].
 64. Markey K, Mitchell J, Botfield H, Ottridge RS, Matthews T, Krishnan A, et al. 11beta-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. *Brain Commun*. 2020;2(1):fcz050. [PMID: 32954315, PMCID: PMC7425517, <https://doi.org/10.1093/braincomms/fcz050>].
 65. Goodpaster BH, Sparks LM. Metabolic Flexibility in Health and Disease. *Cell Metab*. 2017;25(5):1027-36. [PMID: 28467922, PMCID: PMC5513193, <https://doi.org/10.1016/j.cmet.2017.04.015>].
 66. Mariniello B, Ronconi V, Rilli S, Bernante P, Boscaro M, Mantero F, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. *Eur J Endocrinol*. 2006;155(3):435-41. [PMID: 16914598, <https://doi.org/10.1530/eje.1.02228>].